Histamine-release haemodynamic changes produced by rocuronium, vecuronium, mivacurium, atracurium and tubocurarine. 1995

M Naguib, and A H Samarkandi, and H S Bakhamees, and M A Magboul, and A K el-Bakry
Department of Anaesthesia, King Saud University, Faculty of Medicine at King Khalid University Hospital, Riyadh, Saudi Arabia.

We have examined the effects of different benzyl-isoquinolinium and steroidal neuromuscular blocking compounds on plasma concentrations of histamine, heart rate and arterial pressure in surgical patients. A single, rapid (5-s) bolus of mivacurium 0.2 mg kg-1, atracurium 0.6 mg kg-1, tubocurarine 0.5 mg kg-1, vecuronium 0.1 mg kg-1 or rocuronium 0.6 mg kg-1 was administered to 75 patients (n = 15 in each group). Anaesthesia was induced with thiopentone 6 mg kg-1 i.v. and maintained with isoflurane and 70% nitrous oxide in oxygen. Venous blood samples were obtained before induction, 1 min after thiopentone and 1, 3 and 5 min after administration of the neuromuscular blocking drug. Mivacurium, atracurium and tubocurarine caused 370%, 234% and 252% increases in plasma histamine concentrations at 1 min, respectively. Corresponding values at 3 min were 223%, 148% and 157%, respectively. These changes were significant (P < 0.01) at 1 and 3 min. In contrast, the rocuronium and vecuronium groups had no significant changes in either plasma histamine concentrations or haemodynamic variables.

UI MeSH Term Description Entries
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003473 Neuromuscular Nondepolarizing Agents Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. Curare-Like Agents,Curariform Drugs,Muscle Relaxants, Non-Depolarizing,Neuromuscular Blocking Agents, Competitive,Nondepolarizing Blockers,Agents, Curare-Like,Agents, Neuromuscular Nondepolarizing,Blockers, Nondepolarizing,Curare Like Agents,Drugs, Curariform,Muscle Relaxants, Non Depolarizing,Non-Depolarizing Muscle Relaxants,Nondepolarizing Agents, Neuromuscular
D005260 Female Females
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006632 Histamine An amine derived by enzymatic decarboxylation of HISTIDINE. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. Ceplene,Histamine Dihydrochloride,Histamine Hydrochloride,Peremin
D006636 Histamine Release The secretion of histamine from mast cell and basophil granules by exocytosis. This can be initiated by a number of factors, all of which involve binding of IgE, cross-linked by antigen, to the mast cell or basophil's Fc receptors. Once released, histamine binds to a number of different target cell receptors and exerts a wide variety of effects. Histamine Liberation,Histamine Liberations,Histamine Releases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077123 Rocuronium An androstanol non-depolarizing neuromuscular blocking agent. It has a mono-quaternary structure and is a weaker nicotinic antagonist than PANCURONIUM. Androstane-3,17-diol, 2-(4-morpholinyl)-16-(1-(2-propen-1-yl)-1-pyrrolidiniumyl)-, 17-acetate, (2beta,3alpha,5alpha,16beta,17beta)-,1-(17-(Acetoyl)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)pyrrolidinium,Esmeron,Esmerone,ORG 9426,ORG-9426,Pyrrolidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)-, bromide,Rocuronium Bromide,Zemuron,ORG9426

Related Publications

M Naguib, and A H Samarkandi, and H S Bakhamees, and M A Magboul, and A K el-Bakry
June 2004, Journal of the Egyptian National Cancer Institute,
M Naguib, and A H Samarkandi, and H S Bakhamees, and M A Magboul, and A K el-Bakry
September 1998, Anaesthesia,
M Naguib, and A H Samarkandi, and H S Bakhamees, and M A Magboul, and A K el-Bakry
January 1985, Annales francaises d'anesthesie et de reanimation,
M Naguib, and A H Samarkandi, and H S Bakhamees, and M A Magboul, and A K el-Bakry
November 1996, International journal of clinical monitoring and computing,
M Naguib, and A H Samarkandi, and H S Bakhamees, and M A Magboul, and A K el-Bakry
November 1994, Anesthesia and analgesia,
M Naguib, and A H Samarkandi, and H S Bakhamees, and M A Magboul, and A K el-Bakry
October 1996, Anesthesia and analgesia,
M Naguib, and A H Samarkandi, and H S Bakhamees, and M A Magboul, and A K el-Bakry
January 1983, British journal of anaesthesia,
M Naguib, and A H Samarkandi, and H S Bakhamees, and M A Magboul, and A K el-Bakry
July 1995, Anesthesia and analgesia,
M Naguib, and A H Samarkandi, and H S Bakhamees, and M A Magboul, and A K el-Bakry
January 1997, Anaesthesiologie und Reanimation,
M Naguib, and A H Samarkandi, and H S Bakhamees, and M A Magboul, and A K el-Bakry
April 1997, Der Anaesthesist,
Copied contents to your clipboard!